



RECEIVED

APR 25 2001

TECH CENTER 1600/2900

GAU 1624

Patent Application  
Attorney Docket No. PC10228A

#9 B

4/27/01

PS

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, addressed to the Commissioner for Patents, Washington, DC 20231, on this 19th day of April 2001.

By

(Signature of person mailing)

E. Victor Donahue

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Farzan Rastinejad et al. :

APPLICATION NO.: 09/443,542 : Examiner: Richard L. Raymond

FILING DATE: November 19, 1999 : Group Art Unit: 1624

TITLE: METHODS AND COMPOSITIONS FOR :  
RESTORING CONFORMATIONAL  
STABILITY OF A PROTEIN OF THE P53  
FAMILY

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Reply to Requirement of Restriction and Election including  
Preliminary Amendment

The present Reply is in response to the Requirement of Restriction and Election mailed by the Examiner herein on March 22, 2001.

**Applicants request examination of the Group II claims, that is, Nos. 9-23.**

To facilitate examination, Applicants now present replacement claims directed to the elected group II invention. These claims are Nos. 26-35 shown below, and examination may be limited to these claims. The claims are also limited to the **disease state of cancer**, again to facilitate examination.

As soon as a continuation application can be filed, Applicants will then cancel claims 1-25 from the present application. Cancellation is without prejudice to the presentation of these claims, and the subject matter thereof, in further continuation or divisional applications.

Since claims reciting particular chemical species are no longer pending, it is believed that the election requirement under 35 USC 121/ 37 CFR 1.146 has been made moot. However, to facilitate examination herein, Applicants respectfully direct attention to the disclosure in the Specification concerning the compound known as N-{2-[2-(4-Methoxyphenyl)-vinyl]-quinazolin-4-yl}-N',N'-dimethyl-propane-1,3-diamine hydrochloride. The